Circulating tumor cells (CTCs) exist in low quantities in the bloodstream in the early stages of cancers. It, therefore, remains a technical challenge to isolate them in large enough quantities for a precise diagnosis and downstream analysis. We introduce the BMProbe™, a minimally invasive device that isolates CTCs during a 30-minute incubation in the median cubital vein. The optimized geometry of the device creates flow conditions for improved cell deposition. The CTCs are isolated using antibodies that are bound to the surface of the BMProbe™. In this study, flow experiments using cell culture cells were conducted. They indicate a 31 times greater cell binding efficiency of the BMProbe™ compared to a flat geometry. Further, the functionality of isolating CTCs from patient blood was verified in a small ex vivo study that compared the cell count from seven non-small-cell lung carcinoma (NSCLC) patients compared to nine healthy controls with 10 mL blood samples. The median cell count was 1 in NSCLC patients and 0 in healthy controls. In conclusion, the BMProbe™ is a promising method to isolate CTCs in large quantities directly from the venous bloodstream without removing blood from a patient. The future step is to verify the functionality in vivo.
13 May 2026 in Frontiers in Mechanical Engineering
Background: Wall shear stress (WSS), defined as the product of the wall shear rate and dynamic viscosity, is a key regulator of vascular biology. In vivo , WSS ranges from 100 Pa in stenotic vessels. It influences hemostasis, thrombosis, atherosclerosis and endothelial cell behavior by modulating platelet deposition, ion channel activation and gene expression. To study these processes in vitro , flow chambers such as the ibidi µ-Slide VI 0.4 are widely used, enabling cell culture under defined shear stress and live-cell imaging. While typically applied at WSS ≤1 Pa, usage with higher stresses have also been reported in literature. During our experiments, however, we observed inhomogeneous flow in the ibidi µ-Slide VI 0.4 . Methods: To confirm these observations, a Computational Fluid Dynamic simulation of the flow chamber was conducted. The simulation was first validated by PIV experiments in the center layer of the channel at two different volume flows. The results were compared to the numerical simulation and the analytical results, which are based on the manufacturer’s application note with reference to literature. Results: In contrast to the analytical results and the manufacturer’s specifications, the numerical results show velocity variations in the center layer of the channel, which increase with higher volume flow. This phenomenon is confirmed by experimental data. Simulation of the WSS on the channel bottom shows that, at low volume flows, WSS is relatively homogeneous and matches expected values. However, inhomogeneities increase with higher flow above 23.66 mL/min, where the deviation from the expected WSS is 10%. The data also reveal relatively high WSS near the lateral walls of the channel as well as increased velocities near the channel bottom at the inlet area. This results in secondary flow and inhomogeneous velocities at the wall along the channel. Conclusion: This study highlights limitations of the ibidi µ-Slide VI 0.4 at elevated WSS. The findings indicate that increasing volume flow leads to heterogeneous wall conditions, which may strongly influence cell experiments.
Background/Objectives: Liquid biopsy is a minimally invasive alternative to tissue biopsy and is used to obtain information about a disease from a blood sample or other body fluids. In the context of cancer, circulating tumor cells (CTC) can be used as biomarkers to determine the nature of the tumor, its stage of progression, and the efficiency of the administered therapy through monitoring. However, the low concentration of CTCs in blood (1–10 cells/mL) is a challenge for their isolation. Therefore, a minimally invasive medical device (BMProbe™) was developed that isolates CTCs via antigen–antibody binding directly from the bloodstream. Current investigations focus on the process of detaching bound cells from the BMProbe™ surface for cell cultivation and subsequent drug testing to enable personalized therapy planning. Methods: This article presents two approaches for detaching LNCaP cells from anti-EpCAM coated BMProbes™: enzymatic detachment using TrypLE™ and detachment through enzymatic pretreatment with supplementary flow-induced shear stress. The additional shear stress is intended to increase the detachment efficiency. To determine the flow rate required to gently detach the cells, a computational fluid dynamics (CFD) simulation was carried out. Results: The experimental test results demonstrate that 91% of the bound cells can be detached enzymatically within 10 min. Based on the simulation, a maximum flow rate of 47.76 mL/min was defined in the flow detachment system, causing an average shear stress of 8.4 Pa at the probe edges. The additional flow treatment did not increase the CTC detachment efficiency. Conclusions: It is feasible that the detachment efficiency can be further increased by a longer enzymatic incubation time or higher shear stress. The influence on the integrity and viability of cells must, however, be considered.